Cellvie
Cellvie is a pioneering biotechnology company developing medicines from cells, with a focus on leveraging the therapeutic potential of mitochondria. Founded in 2018 and headquartered in Zurich, Switzerland, the company is advancing a novel treatment modality called Therapeutic Mitochondria Transplantation, aimed at addressing conditions such as ischemia-reperfusion injury, aging, and other diseases related to mitochondrial dysfunction. Cellvie's mission is to bring this innovative technology to patients in need, transforming the landscape of regenerative medicine and cellular therapies.
Industries
Nr. of Employees
small (1-50)
Products
Allogeneic, off-the-shelf mitochondrial therapy for ischemia-reperfusion injury (kidney transplantation)
An investigational allogeneic mitochondrial product intended for administration during organ transplantation to reduce ischemia-reperfusion damage and lower incidence of delayed graft function.
Mitochondria-enabled gene therapy delivery platform
A platform approach using isolated mitochondria as delivery vectors for oligonucleotides and genetic payloads to solid organs, aiming to achieve tissue-specific delivery with larger payload capacity than conventional vectors.
Allogeneic, off-the-shelf mitochondrial therapy for ischemia-reperfusion injury (kidney transplantation)
An investigational allogeneic mitochondrial product intended for administration during organ transplantation to reduce ischemia-reperfusion damage and lower incidence of delayed graft function.
Mitochondria-enabled gene therapy delivery platform
A platform approach using isolated mitochondria as delivery vectors for oligonucleotides and genetic payloads to solid organs, aiming to achieve tissue-specific delivery with larger payload capacity than conventional vectors.
Services
Manufacturing process development collaboration (automation & scale-up)
Collaborative R&D and engineering project to advance mitochondrial isolation, automation and scalable GMP-capable manufacturing processes to enable safe, cost-effective production.
Manufacturing process development collaboration (automation & scale-up)
Collaborative R&D and engineering project to advance mitochondrial isolation, automation and scalable GMP-capable manufacturing processes to enable safe, cost-effective production.
Expertise Areas
- Therapeutic mitochondria transplantation
- Ischemia-reperfusion injury therapeutics
- Organ transplantation applications (kidney transplantation)
- Mitochondria-enabled gene and oligonucleotide delivery
Key Technologies
- Therapeutic organelle transplantation
- Mitochondria isolation and purification
- Cryopreservation and organelle formulation
- Mitochondria-mediated oligonucleotide delivery